Use this link to cite:
http://hdl.handle.net/2183/40681 Unprecedented Inhibition of P-gp Activity by a Novel Ruthenium-Cyclopentadienyl Compound Bearing a Bipyridine-Biotin Ligand
Loading...
Identifiers
Publication date
Authors
Côrte-Real, Leonor
Karas, Brittany
Gírio, Patrícia
Moreno, Alexis
Marques, Fernanda
Buckley, Brian T.
Cooper, Keith R.
Doherty, Cathleen
Falson, Pierre
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Leonor Côrte-Real, Brittany Karas, Patrícia Gírio, Alexis Moreno, Fernando Avecilla, Fernanda Marques, Brian T. Buckley, Keith R. Cooper, Cathleen Doherty, Pierre Falson, M. Helena Garcia, Andreia Valente, Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand, European Journal of Medicinal Chemistry, Volume 163, 2019, Pages 853-863, ISSN 0223-5234, https://doi.org/10.1016/j.ejmech.2018.12.022
Type of academic work
Academic degree
Abstract
[Abstract] Two new ruthenium complexes, [Ru(η5-Cp)(PPh3)(2,2’-bipy-4,4’-R)]+ with R = -CH2OH (Ru1) or dibiotin ester (Ru2) were synthesized and fully characterized. Both compounds were tested against two types of breast cancer cells (MCF7 and MDA-MB-231), showing better cytotoxicity than cisplatin in the same experimental conditions. Since multidrug resistance (MDR) is one of the main problems in cancer chemotherapy, we have assessed the potential of these compounds to overcome resistance to treatments. Ru2 showed exceptional selectivity as P-gp inhibitor, while Ru1 is possibly a substrate. In vivo studies in zebrafish showed that Ru2 is well tolerated up to 1.17 mg/L, presenting a LC50 of 5.73 mg/L at 5 days post fertilization.
Description
This is an accepted version of the published document.
Editor version
Rights
Atribución-NoComercial-SinDerivadas 4.0 Internacional
Collections
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 4.0 Internacional